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Purpose: Presumed ifferences inthe thrombolytic activity and fibrinolytic specificity of the 
three commonly used thrombolytic agents, streptokinase, urokinase, and recombinant 
tissue plasminogen activator (rt-PA), are based on clinical study results, where variability 
renders meaningful comparisons difficult. An in vitro model of catheter-directed venous 
thrombolysis was used to compare the three agents. 
Methods: Retracted iodine 125-radiolabeled clots that simulate those observed in the 
venous ystem were infused with thrombolytic agents at doses analogous to those used 
clinically. Perfusion with heparinized, whole human blood was undertaken for 60 minutes, 
measuring the efficacy of thrombolysis through serial quantification of radio tracer 
released into the circuit. Fibrinolytic specificity was determined by following decrements 
in perfusate fibrinogen concentration. 
Results: Streptokinase was the agent associated with the slowest rate of clot lysis (p = 0.01 
vs urokinase and rt-PA). Urokinase was associated with an intermediate rate of lysis but 
appeared to be the agent with the greatest degree of fibrinolytic specificity (p = 0.02 vs 
streptokinase, p = 0.05 vs rt-PA). Although rt-PA was associated with improved efficacy 
early in the perfusions, the differences between rt-PA and urokinase dissipated after 30 
minutes. 
Conclusions: These laboratory observations suggest hat urokinase may be the most 
appropriate agent for catheter-directed venous thrombolysis, offering an advantageous 
compromise between fibrinolytic specificity and thrombolytic speed. (J VAsc SURG 
1995;22:593-7.) 
Administration of thrombolytic agents into vas- 
cular thrombi has become accepted as a modality 
to recanalize occluded arteries 1-5 and veins. 6-9 At 
present, three commonly used thrombolytic agents 
exist: streptokinase, urokinase, and recombinant 
tissue plasminogen activator (rt-PA). Three mea- 
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sures by which these agents can be compared are 
cost, lytic speed, and fibrinolytic specificity. The 
agents clearly differ with regard to cost, and they 
may also differ with regard to rapidity of throm- 
bolysis and fibrinolytic specificity, l°,u To date, there 
has been relatively scant investigation comparing the 
available thrombolytic agents in an objective, ex- 
perimentally sound manner. The vast number of  
confounding variables such as duration of the oc- 
clusion, anatomic location of the occlusion, and the 
mass of the thrombus makes the performance of a 
clinical study impossible without very large numbers 
of patients. 
We have developed an in vitro experimental 
model that closely resembles the clinical setting) 2A 
rational comparison of the available thrombolytic 
agents can be more easily accomplished in this 
laboratory setting, controlling for such variables as 
the size and consistency of the thrombus and the 
hemodynamic conditions present in the occluded 
conduit during recanalization. Using this in vitro 
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model of thrombolysis, we have compared streptoki- 
nase, urokinase and rt-PA with regard to speed of 
thrombolysis and fibrinolytic specificity. 
MATERIAL AND METHODS 
Material. Streptokinase (KabiVitrum AB, Stock- 
holm, Sweden), uroldnase (Abbott Laboratories, 
North Chicago, Ill.), and rt-PA (Genentech, South 
San Francisco, Calif.) were reconstituted in 5% 
dextrose to achieve final concentrations of 150 U, 
5000 IU, and 80 t~g per ml. Porcine sodium heparin 
(0.75 U/ml, Elkins-Sinn, Cherry Hill, N.J.) was used 
to anticoagulate he whole blood perfusate, raising 
the activated clotting time from 120 _+ 3 seconds to 
268 + 7 seconds. Topical bovine thrombin (Armour 
Pharmaceutical Co, Kankakee, Ill.) and iodine 125- 
labeled fibrinogen (0.813 Ci/ml; ICN Biomedicals, 
Irvine, Calif.) were used to form thrombus. Non- 
thrombogenic plastic tubing and connectors were 
used in the perfusion circuit o minimize activation of 
platelets and the clotting cascade. 12 
Clot formation. Phlebotomy was performed on 
37 healthy volunteers who had not recently received 
antiplatelet agents or oral contraceptive medications, 
drawing a total of 80 ml of blood into syringes 
preloaded with 60 U heparin (0.75 U/ml final 
heparin concentration). Immediately, 10 ml heparin- 
ized blood was combined with 500 IU thrombin and 
1.0 ~Ci 12sI-fibrinogen in a plastic syringe. The 
remaining 70 ml of heparinized blood was saved for 
use as the perfusate. 
Once formed, the clots were incubated for 
90 minutes at 37 ° C and allowed to retract, decanting 
the serum from the syringe. The clots were then 
removed from the syringe, cut into strips, and gently 
packed into 5 cm long, 5 mm internal diameter 
polytetrafluoroethylene segments. The initial amount 
of clot was then quantitated by measuring the ~2~I 
activity of the segment in a gamma counter. The 
efficiency of the gamma counting protocol was 
97.14% to 0.4%. 
Perfusions. The perfusion model was fully de- 
scribed in a previous publication) 2 Thirty-seven 
perfusions were performed in this study, represent- 
ing one perfusion for each volunteer donor. Clots 
were infused with streptokinase (12 perfusions, 10 
U/min), urokinase (15 perfusions, 333 IU/min), or 
rt-PA (10 perfusions, 5.3 meg/rain) at a rate of 0.067 
ml per minute for 60 minutes with use of a 
volumetric infusion pump (Imed Corp, San Diego, 
Calif.). The infusion catheter was threaded into the 
thrombus with the single end-hole located in the 
proximal portion (1.0 cm) of clot. The thrombolytic 
infusion rates and doses were analogous to those 
used clinically, scaling the clinical parameters down 
by a factor of one eleventh to account for differences 
in the mass of thrombus. Calculations were based 
on an average thrombus mass of 11 grams in a 15 cm 
long, 1 cm diameter iliofemoral venous segment, 
versus 1 gm in the 5 cm long, 5 mm diameter 
conduit. 
Phasic perfusate flow was generated with a 
peristaltic pump (Manostat, Varistaltic, Rochester, 
N.Y.) by use of a bypass circuit around the clot- 
containing segment to simulate collateral flow 
around an occluded vein. The temperature of the 
system was maintained at 37 ° C, enclosing the system 
in a lead-lined, thermostatically controlled, heated 
box. Total flow through the perfusion circuit was 
controlled at 40 ml/min. Flow through the polytet- 
rafluoroethylene segments ranged from 0% to 
36%-+ 2% of total flow in the circuit as clot 
dissolution progressed, corresponding to shear ates 
of 0 to 150 sec -1 and analogous to the hemodynamic 
conditions observed in large veins) 3 
Fibrinolytic specificity was assessed by measuring 
the decrement in perfusate fibrinogen over time, 
reasoning that the most fibrin-specific agent would be 
the agent with the least propensity for systemic 
fibrinogen degradation. Fibrinogen concentrations 
were assayed spectrophotometrically by use of the 
method of Clauss, 14 measuring fibrinogen in serial 
aliquots of the perfusate, drawn into tubes preloaded 
with aprotinin (Sigma Chemical Co., St. Louis, Mo.) 
to arrest ongoing fibrinogenolysis. 
Fibrinogen disappearance in the perfusate oc- 
curred almost exclusively as a result of the infusion of 
thrombolytic agents and fibrinogenolysis. The con- 
version of fibrinogen to fibrin in the circuit was mini- 
mal as a result of excess heparin in the perfusate and 
complete inhibition of thrombin. Fibrinopeptide A 
levels, an index of fibrinogen disappearance through 
thrombogenesis, averaged less than 20 ng/ml in 120- 
minute control perfusions performed in the absence 
ofthrombolytic agent. 
Statistics. Data were analyzed over time with use 
of Student's t test and analysis of variance techniques. 
Signifcance was assumed when the two-tailedp value 
was less than 0.05. Data are expressed as mean + 
SEM. 
RESULTS 
Thrombolytic efficacy. Streptokinase was asso- 
ciated with the slowest rate ofthrombolysis (Table I). 
At 60 minutes, only 27% + 8% of the thrombus was 
dissolved (p = 0.01). By contrast, urokinase and 
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Table I. Thrombolytic efficacy (percent clot dissolution) of streptokinase, urokinase, and rt-PA at 
1S-minute intervals over a 60-minute infusion period 
No. 15 rain. 30 rain. 45 rain. 60 rain. 
Streptokinase 12 8% ± 2% 10% + 3% 19% + 5% 27% _+ 8% 
Urokinase 15 12% -+ 3% 31% + 5% 59% ± 7% 64% + 9% 
rt-PA 10 24% ± 7% 54% + 8% 71% ± 10% 66% ± 11% 
rt-PA perfusions dissolved 64% _+ 9% and 66% _+ 
11% of thrombi, respectively, after 60 minutes of 
infusion. Although the final amount of thrombus 
dissolved was equal in the urokinase and rt-PA perfu- 
sions, rt-PA was associated with a more rapid rate of 
thrombolysis early on, averaging 24% _+ 7% versus 
12% _+ 3% in the urokinase perfusions after 15 min- 
utes of infusion (p = 0.07). The urokinase/rt-PA 
differences persisted to 30 minutes (2 = 0.01) but 
had dissipated by 45 minutes of perfusion 
(p = 0.36).  Thus within the context of the doses 
used clinically, streptokinase was the slowest agent, 
uroldnase was intermediate, and rt-PA was the agent 
associated with the most rapid rate of thrombolysis. 
Fibrinolytic specificity. Fibrinogen degradation, 
as an inverse index of fibrinolytic specificity, was 
similar in the three groups at 30 minutes of infu- 
sion (Table I1); however, streptokinase was associ- 
ated a twofold increase in fibrinogen degradation 
when compared with urokinase (25% _+ 5% versus 
12% + 3% at 30 minutes, p = 0.01). After 60 
minutes of perfusion, fibrinogen degradation was 
lowest in the urokinase group, averaging 33% + 5% 
after 60 minutes of infusion (p = 0.02 vs streptoki- 
nase, p = 0.05 vs rt-PA). Streptokinase and rt-PA 
were associated with equal rates of fibrinogen deg- 
radation, averaging 55% -+ 9% and 49% -+ 7%, 
respectively. 
Cost analysis. The clinical cost of a vial of 
streptoldnase atthe time of study was $297 for 1.5 
million units, versus $256 for 250,000 IU urokinase 
and $2217 for 100 mg rt-PA. Expressing the efficacy 
of thrombolysis as a function of the cost of the 
pharmaceutical gent, streptokinase was the most 
cost-efficient agent, followed by urokinase and rt-PA 
(Table III). 
DISCUSSION 
Plasmin, a proteolytic molecule with 790 amino 
acid residues and a molecular weight of 88,000 d, is 
the active agent in thrombolysis)  Fibrin-bound 
plasmin rapidly degrades insoluble fibrin to the 
transient intermediate d gradation products fractions 
X and Y and the soluble nd-products fractions D and 
Table II. Degree of fibrinogen degradation 
associated with streptokinase, uroldnase, 
and rt-PA expressing fibrinogen degradation 
as present of baseline concentration 
Fi&4nogen degradation 
30 mira. 60 rain. 
Streptokinase 25% + 5% 55% _+ 9% 
Urokinase 12% _+ 3% 33% -+ 5% 
rt-PA 18% ± 4% 49% +_ 7% 
E)  6 This process can restore patency to occluded 
vascular segments, and the efficacy of the clinically 
used thrombolytic agents streptokinase, urokinase, 
and rt-PA results from their relative abilities to 
catalyze the conversion of fibrin-hotrod plasminogen 
to plasminJ 7 
The proteolytic activity of plasmin, however, is 
not specific for pathologic fbrin thrombi, s Clearly, 
plasmin generation within the desirable fibrin plugs 
at sites of vascular disintegrity is associated with 
untoward hemorrhagic side effects. Although some 
investigators suggested that one thrombolytic agent 
may have benefits over another with regard to lysis 
of pathologic thrombi versus fibrin plugs, n the 
structural similarity of the two types of thrombi 
made this contention ludicrous. 19 Improvements in
the safety of thrombolytic regimens are more likely 
to be achieved with modifications in the method of 
administration rather than through the use of novel 
plasminogen activators or through efforts to in- 
crease the concentration of lyric agent within the 
thrombus compared with the concentration i the 
systemic plasma milieu) ,3,5 This realization, along 
with the difficulty in achieving any degree of pen- 
etration of lytic agent into large peripheral 
thrombi, 8'2° has fostered the abandonment of sys- 
temic thrombolytic administration in favor of 
catheter-directed approaches in both the arterial 1,2,21 
and venous setting. 7,22,2a 
This laboratory investigation documented throm- 
bolytic efficacy and fibrinolytic specificity of the three 
commonly used thrombolytic agents, streptokinase, 
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Table III. Relative costs and cost-efficiency of streptokinase, urokinase, and rt-PA. * Relative lysis 
is based on the percent clot lysis after 60 minutes, indexed to streptokinase as100. Cost-efficiency is 
defined as the relative lysis per dollar expended. 
Cost/hr treatment~ Relative lysis Cost-efficiency 
Streptokinase $37 100 2.70 
Urokinase $246 237 0.96 
rt-PA $277 244 0.88 
~Relative lysis is based on the percent clot lysis after 60 minutes, indexed to streptokinase as 100. Cost-efficiency is defined as the relative 
lysis per dollar expended. 
tHospital costs, 1995 USD, assumes that a minimum of one vial of agent will be needed to generate an eight hour bag for administration. 
urokinase, and rt-PA. Previous clinical 24 and labora- 
tory investigations have suggested that streptokinase 
is the agent associated with the slowest rate of clot 
dissolution. 15 Our investigation has corroborated 
these findings in a model that closely resembles the 
clinical paradigm associated with catheter-directed 
venous thrombolysis. Other investigations 24 have 
suggested that rt-PA is the agent associated with the 
most rapid rate of thrombolysis. This study con- 
firmed an advantage ofrt-PA over both streptokinase 
and urokinase with respect o thrombolytic rate 
during the early perfusion period. This benefit, 
however, did not persist, with equal rates of clot lysis 
between urokinase and rt-PA during the latter period 
ofperfusion. This later finding is consistent with the 
observations ofMeyerovitz et al.,2s in a randomized 
clinical study comparing rt-PA and uroldnase. More 
recently, the STILE trial 26 did not find significant 
differences between rt-PA and urokinase in patients 
with peripheral arterial occlusion. The somewhat 
higher cost of rt-PA does not therefore appear to 
associated with sufficient lytic efficacy to justify its 
replacement of uroldnase as the agent of choice in 
peripheral arterial or venous thrombolysis. 
rt-PA has been shown experimentally to possess a
higher affinity for fibrin than either streptoldnase or 
urokinase, 27presumably as a result of the kringle 
domain structures of rt-PA, pronglike projections 
homologous to similar structures in plasminogen. 28 
rt-PA was expected to be a "fibrin-specific" agent, 
producing thrombolysis without significant plas- 
minemia, fibrinogen breakdown, and a systemic 
"lyric state." Clinical studies, however, have demon- 
strated that rt-PA is only relatively specific for 
fibrin, 24 and its use is associated with significant 
decrements in plasma fibrinogen and an incidence of 
distant bleeding complications paralleling that of the 
other agents. 29 The laboratory data in this study are 
consistent with a significant degree of systemic 
fibrinogenolysis a sociated with rt-PA. It is possible 
that the relatively large doses of rt-PA necessary to 
achieve rapid thrombolysis overwhelm the throm- 
bolytic system and result in significant free-plasmin 
generation and subsequent systemic fibrinogen deg- 
radation. 
In summary, our laboratory findings confirm that 
streptokinase in the doses used clinically is the least 
efficient hrombolytic agent, with a relatively slow 
rate of thrombolysis and with a significant degree of 
fibrinogenolysis. Urokinase is intermediate in its rate 
of thrombolysis, inferior to rt-PA initially, but equal 
to rt-PA with continued administration, rt-PA ap- 
pears to offer little advantage over urokinase with 
respect to fibrinolytic specificity. These observations, 
taken in conjunction with economic onsiderations, 
suggest that urokinase may be the most appropriate 
agent in catheter-directed v nous thrombolysis. 
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